...
search icon
incy-img

Incyte Corporation, Common Stock

INCY

NSQ

$72.64

+$0.05

(0.07%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$13.99B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
806.5555
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.01M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.71
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$50.35 L
$83.95 H
$72.64

About Incyte Corporation, Common Stock

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation more

Industry: BiotechnologySector: Health Care

Returns

Time FrameINCYSectorS&P500
1-Week Return-1.13%1.27%0.82%
1-Month Return4.93%3.86%2.18%
3-Month Return10.58%-3.02%4.7%
6-Month Return5.9%-3.83%11.65%
1-Year Return20.13%2.89%23.81%
3-Year Return1.47%12.86%40.97%
5-Year Return-4.51%41.93%88.07%
10-Year Return-12.56%103.83%200.64%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue2.16B2.67B2.99B3.39B3.70B[{"date":"2019-12-31","value":58.41,"profit":true},{"date":"2020-12-31","value":72.16,"profit":true},{"date":"2021-12-31","value":80.8,"profit":true},{"date":"2022-12-31","value":91.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue114.25M131.33M150.99M207.00M255.00M[{"date":"2019-12-31","value":44.8,"profit":true},{"date":"2020-12-31","value":51.5,"profit":true},{"date":"2021-12-31","value":59.21,"profit":true},{"date":"2022-12-31","value":81.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit2.04B2.54B2.84B3.19B3.44B[{"date":"2019-12-31","value":59.42,"profit":true},{"date":"2020-12-31","value":73.69,"profit":true},{"date":"2021-12-31","value":82.41,"profit":true},{"date":"2022-12-31","value":92.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin94.71%95.08%94.94%93.90%93.10%[{"date":"2019-12-31","value":99.61,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.86,"profit":true},{"date":"2022-12-31","value":98.77,"profit":true},{"date":"2023-12-31","value":97.92,"profit":true}]
Operating Expenses1.62B2.78B2.23B2.60B2.82B[{"date":"2019-12-31","value":57.54,"profit":true},{"date":"2020-12-31","value":98.42,"profit":true},{"date":"2021-12-31","value":79.24,"profit":true},{"date":"2022-12-31","value":92.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income402.01M(240.29M)585.78M579.44M620.52M[{"date":"2019-12-31","value":64.78,"profit":true},{"date":"2020-12-31","value":-38.72,"profit":false},{"date":"2021-12-31","value":94.4,"profit":true},{"date":"2022-12-31","value":93.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense82.93M29.28M(17.24M)(52.99M)319.89M[{"date":"2019-12-31","value":25.92,"profit":true},{"date":"2020-12-31","value":9.15,"profit":true},{"date":"2021-12-31","value":-5.39,"profit":false},{"date":"2022-12-31","value":-16.56,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income486.79M(232.22M)570.44M529.12M834.22M[{"date":"2019-12-31","value":58.35,"profit":true},{"date":"2020-12-31","value":-27.84,"profit":false},{"date":"2021-12-31","value":68.38,"profit":true},{"date":"2022-12-31","value":63.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes39.88M63.48M(378.14M)188.46M236.62M[{"date":"2019-12-31","value":16.86,"profit":true},{"date":"2020-12-31","value":26.83,"profit":true},{"date":"2021-12-31","value":-159.81,"profit":false},{"date":"2022-12-31","value":79.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes446.91M(295.70M)948.58M340.66M597.60M[{"date":"2019-12-31","value":47.11,"profit":true},{"date":"2020-12-31","value":-31.17,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":35.91,"profit":true},{"date":"2023-12-31","value":63,"profit":true}]
Income From Continuous Operations446.91M(295.70M)948.58M340.66M424.98M[{"date":"2019-12-31","value":47.11,"profit":true},{"date":"2020-12-31","value":-31.17,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":35.91,"profit":true},{"date":"2023-12-31","value":44.8,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income446.91M(295.70M)948.58M340.66M597.60M[{"date":"2019-12-31","value":47.11,"profit":true},{"date":"2020-12-31","value":-31.17,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":35.91,"profit":true},{"date":"2023-12-31","value":63,"profit":true}]
EPS (Diluted)2.84(0.46)2.752.783.52[{"date":"2019-12-31","value":80.68,"profit":true},{"date":"2020-12-31","value":-13.07,"profit":false},{"date":"2021-12-31","value":78.13,"profit":true},{"date":"2022-12-31","value":78.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

INCY
Cash Ratio 1.18
Current Ratio 1.87
Quick Ratio 1.82

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

INCY
ROA (LTM) -0.12%
ROE (LTM) 0.80%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

INCY
Debt Ratio Lower is generally better. Negative is bad. 0.37
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.63

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

INCY
Trailing PE 806.56
Forward PE 11.67
P/S (TTM) 3.43
P/B 4.41
Price/FCF 48
EV/R 3.00
EV/Ebitda 33.57
PEG 0.64

FAQs

What is Incyte Corporation share price today?

Incyte Corporation (INCY) share price today is $72.64

Can Indians buy Incyte Corporation shares?

Yes, Indians can buy shares of Incyte Corporation (INCY) on Vested. To buy Incyte Corporation from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INCY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Incyte Corporation be purchased?

Yes, you can purchase fractional shares of Incyte Corporation (INCY) via the Vested app. You can start investing in Incyte Corporation (INCY) with a minimum investment of $1.

How to invest in Incyte Corporation shares from India?

You can invest in shares of Incyte Corporation (INCY) via Vested in three simple steps:

  • Click on Sign Up or Invest in INCY stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Incyte Corporation shares
What is Incyte Corporation 52-week high and low stock price?

The 52-week high price of Incyte Corporation (INCY) is $83.95. The 52-week low price of Incyte Corporation (INCY) is $50.35.

What is Incyte Corporation price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Incyte Corporation (INCY) is 806.5555

What is Incyte Corporation price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Incyte Corporation (INCY) is 4.41

What is Incyte Corporation dividend yield?

The dividend yield of Incyte Corporation (INCY) is 0.00%

What is the Market Cap of Incyte Corporation?

The market capitalization of Incyte Corporation (INCY) is $13.99B

What is Incyte Corporation’s stock symbol?

The stock symbol (or ticker) of Incyte Corporation is INCY

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top